Skip to content

Spanish Cohort for the Study of the Effect of CPAP in Hypertension (CEPECTA)

Efficacy of the Treatment With Nasal Positive Continuous Airway Pressure to Reduce the Arterial Blood Pressure in Patients With Apneas-Hypopneas During the Sleep and Systemic Hypertension

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00202527
Enrollment
340
Registered
2005-09-20
Start date
2005-01-31
Completion date
2005-09-30
Last updated
2005-12-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension, Sleep Apnea

Keywords

Sleep apnea, Hypertension, CPAP

Brief summary

AIMS:To know the effects of the treatment with nasal positive continuous airway pressure (CPAP) on systemic blood pressure and the expression of biological mediators, in systemic hypertension of recent diagnostic, whose have an apnea-hypopnea index \> 15. METHODOLOGY: DESIGN: Prospective, multicenter, randomized study, of parallel groups and controlled with placebo, in patients diagnosed of systemic hypertension (SH) with an apnea-hypopnea index, by conventional polysomnography \> 15. A total of 340 patients with recently diagnosed of SH and without any pharmacological treatment will be studied. All patients will be randomized to receive, alternatively, CPAP treatment with optimal pressure titled with a proved system, or Sham-CPAP for 12 weeks. MEASUREMENTS: A) Conventional polysomnography at baseline: B) Clinic: sleepiness (ATS, Basic Nordic Sleep Questionnaire and Epworth), quality of life (EuroQol); C) 24 hour blood pressure monitoring; D) Expression of biological mediators in blood: general determinations, endothelial, inflammatory, lipid, renin-angiotensin-aldosterone and adrenergic mediators. ANALYSIS. Baseline measurements of all the variables will be compared with the situation at six and twelve weeks. We will use the chi square test and the Fisher´s exact test (categorical variables), the t test for continous variables and repeated measures ANCOVA for the primary objective. The analyses will be done under the criterion of intention to treat and for protocol. The variables will be controlled by the compliance with the CPAP..

Interventions

DEVICENasal continuos positive airway pressure

Sponsors

Sociedad Española de Neumología y Cirugía Torácica
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Patients, both sexes from 18 to 75 years old, with clinical suspected of OSAH defined by an apnea-hypopnea index \> 15 and having a recent diagnosis of hypertension which have not received any pharmacological treatment for hypertension.

Exclusion criteria

Inclusion Criteria: * Patients with clinical suspected of OSAH defined by an apnea-hypopnea index \> 15 and having a recent diagnosis of hypertension which have not received any pharmacological treatment for hypertension.

Design outcomes

Primary

MeasureTime frame
Effect of CPAP in 24 hours blood pressure monitoring
effect of CPAP y quality of life and clinical aspects

Secondary

MeasureTime frame
effect of CPAP in biologic mediators

Countries

Spain

Contacts

Primary ContactJOAQUIN DURAN-CANTOLLA, MD
joaquin.duran@wanadoo.es34 945 007308

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 30, 2026